KP415 oral capsule

DRUG2 trials

Sponsors

Zevra Therapeutics

Conditions

ADHD

Phase 3

KP415 Classroom Study in Children (6-12 Years of Age) With ADHD

CompletedNCT03292952

Zevra TherapeuticsADHD

Start: 2017-12-20End: 2018-05-16Updated: 2021-06-30

KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD

CompletedNCT03460652

Zevra TherapeuticsADHD

Start: 2018-03-13End: 2019-07-09Updated: 2021-07-19

Related Papers

Serdexmethylphenidate/dexmethylphenidate effects on sleep in children with attention-deficit/hyperactivity disorder

Frontiers in Psychiatry2023-06-233 citations

Analysis of Growth Velocity in Children with Attention-Deficit/Hyperactivity Disorder Treated for up to 12 Months with Serdexmethylphenidate/Dexmethylphenidate

Journal of Child and Adolescent Psychopharmacology2023-05-013 citations

Safety and Tolerability of Serdexmethylphenidate/Dexmethylphenidate Capsules in Children with Attention-Deficit/Hyperactivity Disorder: A 12-Month, Open-Label Safety Study

Journal of Child and Adolescent Psychopharmacology2023-02-216 citations